卡氏肺囊虫性肺炎

Palella FJ, Delaney KM, Moorman FC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.

• 全文
• 摘要

Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the U.S. in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1): 5S-14S.

• 摘要

Pulvirenti J, Herrera P, Venkataraman P, et al. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS. 2003:17:261-265.

• 摘要

Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713-1720.

• 摘要

Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. May 2016. http://aidsinfo.nih.gov/guidelines (last accessed 5 June 2016).

• 全文

Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996;124:585-599.

• 摘要

Broaddus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102:747-752.

• 摘要

Limper AH, Knox KS, Sarosi GA, et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96-128.

• 全文
• 摘要

Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;(4):CD006150.

• 全文
• 摘要

1.  Palella FJ, Delaney KM, Moorman FC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.

• 全文
• 摘要

2.  Kim JH, Psevdos G Jr, Gonzalez E, et al. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection. 2013;41:545-551.

• 摘要

3.  Murray JF, Nadel JA, Mason RJ. Murray and Nadels Textbook of respiratory medicine. 4th ed. 2005, Philadelphia, PA: Elsevier Saunders.

4.  Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999;353:1293-1298.

• 摘要

5.  Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161-5.

• 摘要

6.  Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997;155:60-66.

• 摘要

7.  Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the U.S. in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1): 5S-14S.

• 摘要

8.  Pulvirenti J, Herrera P, Venkataraman P, et al. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS. 2003:17:261-265.

• 摘要

9.  Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS. 2000;14:2559-2566.

• 摘要

10.  Huang L, Hecht FM. Why does Pneumocystis carinii pneumonia still occur? AIDS. 2000;14:2611-2612.

• 摘要

11.  López-Sánchez C, Falcó V, Burgos J, et al. Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era:experience in a university hospital and review of the literature. Medicine (Baltimore). 2015;94:e681.

• 全文
• 摘要

12.  Centers for Disease Control and Prevention (CDC). HIV prevalence estimates: United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:1073-1076.

• 全文
• 摘要

13.  Fisk DT, Meshnick, S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis. 2003;36:70-78.

• 摘要

14.  Taylor SM, Meshnick SR, Worodria W, et al. Low prevalence of Pneumocystis jirovecii lung colonization in Ugandan HIV-infected patients hospitalized with non-Pneumocystis pneumonia. Diagn Microbiol Infect Dis. 2012;72:139-143.

• 摘要

15.  Nesheim SR Kopogiannis BG, Soe SM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics. 2007;120:100-109.

• 摘要

16.  Kovacs A, Frederick T, Church J, et al. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA. 1991;265:1698-1703.

• 摘要

17.  Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713-1720.

• 摘要

18.  Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(RR-8):1-52.

19.  Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26:663-670.

• 摘要

20.  Gilmartin GS, Koziel H. Pneumocystis carinii pneumonia in adult non-HIV disorders. J Intensive Care Med. 2002;17:283-301.

21.  Pareja JGR, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-1224.

• 摘要

22.  Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.

23.  Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127:1242.

• 摘要

24.  Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016;46:11-17.

• 摘要

25.  Ling C, Qian S, Wang Q, et al. Pneumocystis pneumonia in non-HIV children: a 10-year retrospective study. Clin Respir J. 2016 Feb 15 [Epub ahead of print].

• 摘要

26.  Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis Pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013;19:386-392.

• 全文
• 摘要

27.  Harigai M, Koike R, Miyasaka M, et al. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874-1876.

• 摘要

28.  Imaizumi K, Sugishita M, Usui M, et al. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis. Intern Med. 2006;45: 685-688.

• 摘要

29.  Kalyoncu U, Karadag O, Akdogan A, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis. 2007;39:475-478.

• 摘要

30.  Lahiff C, Khiaron OB, Nolan N, et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci. 2007;176:309-311.

• 摘要

31.  Mori S, Imamura S, Fiyofiji C, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16:58-62.

• 摘要

32.  Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. 2013;144:258-265.

• 摘要

33.  Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663-71.

• 摘要

34.  Mansharamani NG, Garland R, Delaney G, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704-711.

• 摘要

35.  Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519-522.

• 摘要

36.  Stringer JR, Cushion MT, Wakefield AE. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol. 2001;Suppl:184S-189S.

• 摘要

37.  Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002 Sep;8(9):891-6.

• 全文
• 摘要

38.  Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204-1209.

• 摘要

39.  Leoung GS. Pneumocystosis and HIV. HIV InSite Knowledge Base. January 2006. http://hivinsite.ucsf.edu (last accessed 5 June 2016).

• 全文

40.  Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegeners granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795-799.

• 摘要

41.  Green H, Paul M, Vidal J, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clinic Proc. 2007;82:1052-1059.

42.  National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2013. http://aidsinfo.nih.gov/guidelines (last accessed 5 June 2016).

• 全文

43.  Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. May 2016. http://aidsinfo.nih.gov/guidelines (last accessed 5 June 2016).

• 全文

44.  Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis. 2010;51:611-619.

• 摘要

45.  Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD005590.

• 全文
• 摘要

46.  Helweg-Larsen J, Tsolaki AJ, Miller RF, et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM. 1998;91:813-820.

• 摘要

47.  Olsson M, Lidman C, Latouche S, et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol. 1998;36:1737-1740.

• 摘要

48.  Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jiroveci transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46:966-971.

• 摘要

49.  Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002;4:95-103.

• 摘要

50.  Zheng M, Shellito JE, Marrero L, et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest. 2001;108:1469-1474.

• 摘要

51.  Wells J, Haidaris CG, Wright TW, et al. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect Immunol. 2006;74:2446-2448.

• 摘要

52.  Theus SA, Smulian AG, Steele P, et al. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine. 1998;16:1149-1157.

• 摘要

53.  Katz MH, Baron RB, Grady D. Risk stratification of ambulatory patients suspected of Pneumocystis pneumonia. Arch Intern Med. 1991;151:105-110.

• 摘要

54.  HIV clinical manual. Singh N, Shafer RW, Swindells S (eds). ESun Technologies;2003.

55.  Fortun J, Navas E, Marti-Belda P, et al. Pneumocystis carinii pneumonia in HIV-infected patients: diagnostic yield of induced sputum and immunofluorescent stain with monoclonal antibodies. Eur Respir J. 1992;5:665-669.

• 摘要

56.  Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589-593.

• 摘要

57.  Midgley J, Parsons P, Leigh TR, et al. Increased sensitivity of immunofluorescence for detection of Pneumocystis carinii. Lancet. 1989;2:1523.

• 摘要

58.  Ng VL, Virani NA, Chaisson RE, et al. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol. 1990;28:2228-2233.

• 摘要

59.  Harcup C, Baier HJ, Pitchenik AE. Evaluation of patients with the acquired immunodeficiency syndrome (AIDS) by fiberoptic bronchoscopy. Endoscopy. 1985;17:217-220.

• 摘要

60.  Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Lancet. 1988 Nov 5;2(8619):1049-51.

• 摘要

61.  Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997;169:967-975.

• 全文
• 摘要

62.  Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Chest. 1999 Apr;115(4):1025-32.

• 全文
• 摘要

63.  Sankary RM, Turner J, Lipavsky A, et al. Alveolar-capillary block in patients with AIDS and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1988;137:443-449.

• 摘要

64.  Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996;124:585-599.

• 摘要

65.  Broaddus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102:747-752.

• 摘要

66.  Fillaux J, Malvy S, Alvarez M, et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jiroveci pneumonia. J Microbiol Methods. 2008;75:258-261.

• 摘要

67.  Tuncer S, Erguven S, Kocagoz S, et al. Comparison of cytochemical staining, immunofluorescence and PCR for diagnosis of Pneumocystis carinii on sputum samples. Scand J Infect Dis. 1998;30:125-128.

• 摘要

68.  Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002;40:490-494.

• 摘要

69.  Helweg-Larsen J, Jensen JS, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 1998;36:2068-2072.

• 摘要

70.  Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis. 2004;189:1679-1683.

• 摘要

71.  Skelly MJ, Holzman RS, Merali S. S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin Infect Dis. 2008;46:467-471.

• 全文
• 摘要

72.  Summah H, Zhu YG, Falagas ME, et al. Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immunocompromised patients: a meta-analysis. Chin Med J (Engl). 2013;126:1965-1973.

• 摘要

73.  Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128-1131.

• 全文
• 摘要

74.  Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009;9:47.

• 全文
• 摘要

75.  Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009;47:3871-3874.

• 全文
• 摘要

76.  Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009;16:1524-1526.

• 全文
• 摘要

77.  Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48:195-202.

• 全文
• 摘要

78.  Huang L. Clinical and translational research in pneumocystis and pneumocystis pneumonia. Parasite. 2011;18:3-11.

• 摘要

79.  Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7-15.

• 全文
• 摘要

80.  Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011;53:197-202.

• 全文
• 摘要

81.  Wood BR, Komarow L, Zolopa AR, et al. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS. 2013;27:967-972.

• 摘要

82.  Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med. 1992;152:1390-1398.

• 摘要

83.  Sandhu JS, Goodman PC. Pulmonary cysts associated with Pneumocystis carinii pneumonia in patients with AIDS. Radiology. 1989;173:33-35.

• 摘要

84.  Abd AG, Nierman DM, Ilowite JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988 Aug;94(2):329-31.

• 全文
• 摘要

85.  Aberg JA. Coccidioidomycosis and HIV. HIV InSite Knowledge Base. March 2006. http://hivinsite.ucsf.edu/ (last accessed 5 June 2016).

• 全文

86.  Drew WL, Lalezari JP. Cytomegalovirus and HIV. HIV InSite Knowledge Base. May 2006. http://hivinsite.ucsf.edu/ (last accessed 5 June 2016).

• 全文

87.  Young EM, Goldman H. Histoplasmosis and HIV infection. HIV InSite Knowledge Base. March 2006. http://hivinsite.ucsf.edu/ (last accessed 5 June 2016).

• 全文

88.  Krown SE. Clinical characteristics of Kaposi sarcoma. HIV InSite Knowledge Base. February 2006. http://hivinsite.ucsf.edu/ (last accessed 5 June 2016).

• 全文

89.  Limper AH, Knox KS, Sarosi GA, et al. An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96-128.

• 全文
• 摘要

90.  Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521-1527.

• 摘要

91.  Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124:792-802.

• 摘要

92.  Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jiroveci pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008;48:63-67.

• 摘要

93.  Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451-1457.

• 摘要

94.  Bozzette SA. The use of corticosteroids in Pneumocystis carinii pneumonia. J Infect Dis. 1990;162:1365-1369.

• 摘要

95.  Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444-1450.

• 摘要

96.  Montaner JS, Lawson LM, Levitt L, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;113:14-20.

• 摘要

97.  Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. J Acquir Immune Defic Syndr. 1992;5:726-731.

• 摘要

98.  Walmsley S, Levinton C, Brunton J, et al. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:348-357.

• 摘要

99.  Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;(4):CD006150.

• 全文
• 摘要

100.  Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med. 2004;128:1023-1027.

• 摘要

101.  Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine. Clin Infect Dis. 2005;40:S131.

• 全文

102.  Briel M, Bucher HC, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006(3):CD006150.

• 摘要

103.  Di Cocco P, Orlando G, Bonanni L, et al. A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc. 2009;41:1201-1203.

• 摘要

104.  Annaloro C, Della Volpe A, Usardi P, et al. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis. 2006;25:52-54.

• 摘要

105.  Hof H, Schnulle P. Pneumocystis jiroveci pneumonia in a patient with Wegeners granulomatosis treated efficiently with caspofungin. Mycoses. 2008;51(suppl 1):65-67.

• 摘要

106.  Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother. 1998;42:1985-1989.

• 摘要

107.  Utili R, Durante-Mangoni E, Basilico C, et al. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007;84:685-688.

• 摘要

108.  Waters L, Nelson A. The use of caspofungin in HIV-infected individuals. Expert Opin Investig Drugs. 2007;16:899-908.

109.  Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001;183:1409-1412.

• 全文
• 摘要

110.  Arozullah AM, Yarnols PR, Weinstein RA, et al. A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era. Am J Respir Crit Care Med. 2000;161:1081-1086.

• 摘要

111.  Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jiroveci pneumonia in HIV-infected patients: 1985 to 2006. Clin Infect Dis. 2008;46:625-633.

• 摘要

112.  Morris A, Creasman J, Turner J, et al. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med. 2002;166:262-267.

• 摘要

113.  Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med. 2000;160:541-547.

• 摘要

114.  Powell K, Davis JL, Morris AM, et al. Survival for patients with human immunodeficiency virus admitted to the intensive care unit continues to improve in the current era of highly active antiretroviral therapy. Chest. 2009;135:11-17.

• 摘要

115.  Wachter RM, Luce JM, Safrin S, et al. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA. 1995;273:230-235.

• 摘要

116.  Wachter RM, Luce JM, Turner J, et al. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis. 1986;134:891-896.

• 摘要

117.  Wachter RM, Russi MB, Bloch DA, et al. Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis. 1991;143:251-256.

• 摘要

118.  Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003;17:73-80.

• 摘要

119.  Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995;155:2436-2441.

120.  Cao B, Wang H, Wang P, et al. Clinical parameters and outcomes of Pneumocystis jiroveci pneumonia in non-HIV/AIDS patients. Chin Med J (Engl). 2006;119:234-237.

• 摘要

121.  Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med. 1991;114:455-459.

• 摘要

122.  DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987 Mar;91(3):323-7.

• 全文
• 摘要

123.  Metersky ML, Colt HG, Olson LK, et al. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest. 1995;108:946-951.

• 摘要

124.  Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68:191-208.

• 摘要

125.  Lawn SD, Török ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis. 2011;24:34-42.

• 摘要